Since the number of formalin-fixed, paraffin-embedded (FFPE) tumor samples collected before treatment with alectinib (n = 38) or crizotinib (n = 31) was limited, we assessed the relationship between both drugs and estimated hazard ratios (HR) using the various cut-off values for basal FGFR1 or FGF2 mRNA expression levels in tumors before starting the treatment determined by RNA sequencing, and estimated the HR of high to low-expression levels in each subset (Supplementary Fig. 5B). This evidence concerns the gene FGFR1 and neoplasm.